Colorectal cancer (CRC) is one of the more common cancers in the United States with over
145,000 new cases expected in 2005. Surgery is the main treatment for CRC. However for some
who relapse after surgery, or are unable to have surgery, chemotherapy is the primary
treatment for this more advanced CRC. Some chemotherapy drugs are given to the patient by
themselves, but many are given in combination with other chemotherapy treatment drugs and
they seem to work better together than by themselves. This study will investigate the
effectiveness of the combination of three chemotherapy drugs in patients who have been
previously treated for their CRC and it has returned. This study will also evaluate any rash
that is associated with the drug Cetuximab. The three therapy drugs are Mitomycin C,
Irinotecan, and Cetuximab.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center